Lenalidomide Plus Rituximab for Recurrent/Refractory CNS and Intraocular Lymphoma

NCT01542918 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

14

Enrollment

OTHER

Sponsor class

Conditions

Recurrent/Refractory CNS
Intraocular Lymphoma

Interventions

DRUG: Lenalidomide
DRUG: Rituximab

Sponsor

James Rubenstein

Collaborators

[object Object]
[object Object]